Karin Melanie Cabanillas Stanchi1, Manon Queudeville1, Carmen Malaval1, Judith Feucht1, Patrick Schlegel1, Markus Dobratz1, Christian Seitz1, Ingo Müller2, Peter Lang1, Rupert Handgretinger1, Michaela Döring3. 1. Department I-General Pediatrics, Haematology/Oncology, University Hospital Tübingen-Children's Hospital, Hoppe-Seyler-Str.1, 72076, Tübingen, Germany. 2. Division of Pediatric Stem Cell Transplantation and Immunology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. 3. Department I-General Pediatrics, Haematology/Oncology, University Hospital Tübingen-Children's Hospital, Hoppe-Seyler-Str.1, 72076, Tübingen, Germany. michaela.doering@med.uni-tuebingen.de.
Abstract
PURPOSE: To evaluate serum procalcitonin (PCT) and C-reactive protein (CRP) as diagnostic biomarkers of transplant-related adverse events (TRAE) in pediatric patients undergoing hematopoietic stem cell transplantation (HSCT). METHODS: This study analyzed PCT and CRP levels of 214 pediatric patients with a median age of 8.5 years (0.4-17.8 years) undergoing allogeneic HSCT with respect to major TRAE. RESULTS: 26 patients (12.1%) did not experience TRAE (control group), and 188 (87.9%) experienced median 2 (range 1-4) TRAE. Median CRP and PCT were highly and significantly increased during sepsis/SIRS and bacteremia (17.24 mg/dl | 6.30 ng/ml; p < 0.0001 vs. prior values), graft rejection (14.73 mg/dl | 3.20 ng/ml; p < 0.0001), and liver GvHD (6.88 mg/dl | 2.29 ng/ml; p < 0.01). Strong CRP increases and slight/minimal/no PCT increases occurred during fungemia (8.85 mg/dl | 0.72 ng/ml; p < 0.001), intestinal GvHD (8.73 mg/dl | 1.06 ng/ml; p < 0.0001), VOD (10.84 mg/dl | 0.59 ng/ml; p < 0.01), mucositis (8.84 mg/dl | 0.81 ng/ml; p < 0.0001), and viremia (3.62 mg/dl; p < 0.0001 | 0.43 ng/ml; below normal limit). During skin GvHD, CRP and PCT were slightly increased (2.03 mg/dl | 0.93 ng/ml; p < 0.0001). CONCLUSIONS: CRP and PCT did not show congruent changes during TRAE. PCT was a clinically relevant marker for the early detection and differentiation of severe mucositis and sepsis/SIRS and bacteremia during the critical neutropenic period after HSCT. PCT helped to discriminate acute intestinal GvHD from adenovirus viremia and liver GvHD from hepatic VOD. Thus, PCT may be a valuable parameter to enable a prompt and appropriate treatment during these complications, improving patient outcomes.
PURPOSE: To evaluate serum procalcitonin (PCT) and C-reactive protein (CRP) as diagnostic biomarkers of transplant-related adverse events (TRAE) in pediatric patients undergoing hematopoietic stem cell transplantation (HSCT). METHODS: This study analyzed PCT and CRP levels of 214 pediatric patients with a median age of 8.5 years (0.4-17.8 years) undergoing allogeneic HSCT with respect to major TRAE. RESULTS: 26 patients (12.1%) did not experience TRAE (control group), and 188 (87.9%) experienced median 2 (range 1-4) TRAE. Median CRP and PCT were highly and significantly increased during sepsis/SIRS and bacteremia (17.24 mg/dl | 6.30 ng/ml; p < 0.0001 vs. prior values), graft rejection (14.73 mg/dl | 3.20 ng/ml; p < 0.0001), and liver GvHD (6.88 mg/dl | 2.29 ng/ml; p < 0.01). Strong CRP increases and slight/minimal/no PCT increases occurred during fungemia (8.85 mg/dl | 0.72 ng/ml; p < 0.001), intestinal GvHD (8.73 mg/dl | 1.06 ng/ml; p < 0.0001), VOD (10.84 mg/dl | 0.59 ng/ml; p < 0.01), mucositis (8.84 mg/dl | 0.81 ng/ml; p < 0.0001), and viremia (3.62 mg/dl; p < 0.0001 | 0.43 ng/ml; below normal limit). During skin GvHD, CRP and PCT were slightly increased (2.03 mg/dl | 0.93 ng/ml; p < 0.0001). CONCLUSIONS: CRP and PCT did not show congruent changes during TRAE. PCT was a clinically relevant marker for the early detection and differentiation of severe mucositis and sepsis/SIRS and bacteremia during the critical neutropenic period after HSCT. PCT helped to discriminate acute intestinal GvHD from adenovirus viremia and liver GvHD from hepatic VOD. Thus, PCT may be a valuable parameter to enable a prompt and appropriate treatment during these complications, improving patient outcomes.
Authors: Philippe Armand; Haesook T Kim; Corey S Cutler; Vincent T Ho; John Koreth; Edwin P Alyea; Robert J Soiffer; Joseph H Antin Journal: Blood Date: 2007-01-18 Impact factor: 22.113
Authors: Stephen T Sonis; Linda S Elting; Dorothy Keefe; Douglas E Peterson; Mark Schubert; Martin Hauer-Jensen; B Nebiyou Bekele; Judith Raber-Durlacher; J Peter Donnelly; Edward B Rubenstein Journal: Cancer Date: 2004-05-01 Impact factor: 6.860
Authors: S Jacobs; C Baggott; R Agarwal; T Hesser; T Schechter; P Judd; D Tomlinson; J Beyene; L Sung Journal: Br J Cancer Date: 2013-10-15 Impact factor: 7.640
Authors: Fabian J S van der Velden; Gabriella de Vries; Alexander Martin; Emma Lim; Ulrich von Both; Laura Kolberg; Enitan D Carrol; Aakash Khanijau; Jethro A Herberg; Tisham De; Rachel Galassini; Taco W Kuijpers; Federico Martinón-Torres; Irene Rivero-Calle; Clementien L Vermont; Nienke N Hagedoorn; Marko Pokorn; Andrew J Pollard; Luregn J Schlapbach; Maria Tsolia; Irini Elefhteriou; Shunmay Yeung; Dace Zavadska; Colin Fink; Marie Voice; Werner Zenz; Benno Kohlmaier; Philipp K A Agyeman; Effua Usuf; Fatou Secka; Ronald de Groot; Michael Levin; Michiel van der Flier; Marieke Emonts Journal: Eur J Pediatr Date: 2022-10-15 Impact factor: 3.860